Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TroVax + interleukin-2
- Development stage
- Unknown
- Lead developer
- Oxford BioMedica
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
TroVax + interleukin-2 is a combination immunotherapy composed of the cancer vaccine TroVax (an engineered modified vaccinia Ankara virus expressing the tumor-associated antigen 5T4) and interleukin-2 (IL-2, a recombinant cytokine). TroVax stimulates the immune system, inducing both humoral and cellular immune responses against cells expressing the 5T4 oncofetal antigen, which is present on various solid tumors. Interleukin-2 promotes the proliferation and activation of T cells, thereby potentiating immune responses. The combination has been investigated for potential additive or synergistic effects in promoting anti-tumor immunity, particularly in metastatic renal cell carcinoma and metastatic colorectal cancer. Clinical studies report induced 5T4-specific antibody and T-cell responses with observed improved survival in some patient cohorts, and combination with IL-2 may be more effective than either agent alone for certain patients[3].
- Other names
- MVA-5T4 + interleukin-2
02
Targets
IL2RB (IL-2 receptor beta chain)TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on TroVax + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TroVax + interleukin-2.